CRUSE^® -An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria.

"CONFLICT OF INTEREST STATEMENT J. Bousquet has received an honorarium for lectures or advisory boards from AstraZeneca, GlaxoSmithKline, Meda, Menarini, Novartis, Uriach, and Viatris. He is a partial shareholder of Kyomed Innov and MASK‐air SAS. K. Weller or recently was a speaker and/or advisor for and/or has received research funds from Moxie, Novartis, Pharvaris, Shire, Takeda, and Uriach. M. Metz is or recently was a speaker and/or consultant for Amgen, AstraZeneca, Argenx, Celldex, Celltrion, Escient, Jasper Therapeutics, Novartis, Pharvaris, Regeneron, Sanofi, and ThirdHarmonicBio. M. Magerl is an advisor for Moxie. E. Kocatürk has been a speaker and has served on advisory boards for Novartis, Menarini, LaRoche Posey, Sanofi, Bayer, Abdi İbrahim, and Pfizer. I. Cherrez‐Ojeda is or recently was a speaker for Sanofi Aventis and Megalabs. A. M. Gimenez‐Arnau or recently was a speaker and/or advisor for and/or has received research funding from Almirall, Amgen, AstraZeneca, Avene, Celldex, Escient Pharmaceuticals, Genentech, GlaxoSmithKline, Instituto Carlos III‐ FEDER, Leo Pharma, Menarini, Mitsubishi Tanabe Pharma, Novartis, Sanofi–Regeneron, Servier, Thermo Fisher Scientific, and Uriach Pharma/Neucor. S. Altrichter has no conflicts of interest in relation to this manuscript. Outside it, she has conducted studies for/was an advisor for/was a speaker for AstraZeneca, Allakos, ALK, Biocryst, CSLBehring, LeoPharma, Moxie, Novartis, Sanofi, Takeda, and Thermofisher. L. F. Ensina has no conflicts of interest in relation to this manuscript. He has conducted studies for Novartis, Amgen, and Sanofi, has been a speaker for Novartis, Sanofi and Abbvie, and has served on advisory boards for Sanofi. L. Bouillet has consulted/served as a speaker for, engaged in research and educational projects with, or accepted travel grants from the following companies: BioCryst, CSL Behring, Takeda, Novartis, GlaxoSmithKline, Blueprint, Intellia, Astra Zeneca, Pharvaris, and Kalvista. R. Asero is or recently was a speaker and/or advisor for GlaxoSmithKline, HAL allergy Malesci, Menarini, Lofarma, Thermo Fisher, Novartis, and Sanofi. M. Gonçalo has been a speaker and/or advisor for Abbvie, AstraZeneca, Leo Pharma, Lilly, Novartis, Pfizer, Sanofi, and Takeda. K. Rutkowski has been a speaker and has served on advisory boards for Novartis. J. A. Bernstein has been a Principal Investigator/Consultant for Sanofi‐Regeneron, AstraZeneca, Novartis, Genentech, Amgen, Allakos, Takeda/Shire, CSL Behring, Biocryst, Pharming, Kalvista, Ionis, Pharvaris, Escient, Astria, Celldex, Biomarin, Blueprint Medicine, and Cogent. Z. Brzoza has been a speaker for Novartis. J. I. L. Sousa has been a speaker for Novartis, Sanofi and Faes Farma. S. F. Thomsen has been a speaker or has served on advisory boards for Sanofi, AbbVie, LEO Pharma, Pfizer, Eli Lilly, Novartis, UCB Pharma, Union Therapeutics, Almirall, and Janssen Pharmaceuticals and has received research support from Sanofi, AbbVie, Leo Pharma, Novartis, UCB Pharma, and Janssen Pharmaceuticals, with no relation to the present manuscript. M. van Doorn or recently was a speaker and/or advisor for and/or has received research funding from Novartis, AbbVie, Pfizer, LEO Pharma, Sanofi, Lilly, Janssen, UCB, BMS, Celgene, and Third Harmonic outside the submitted work. J. Peter has been a speaker or has served on advisory boards for Sanofi, Novartis, Abbivie, Janssen Pharmaceuticals, Takeda, CSL Behring, Pharming, Phavaris, and Astria Therapeutics. M. Hide has been a speaker or has served on advisory boards for Kaken Pharmaceutical, Kyowa Kirin, Kyorin, Mitsubishi Tanabe Pharma, Novartis, Sanofi, Taiho Pharmaceutical, Takeda, Teikoku Seiyaku, and Tori. Y. Ye has been a speaker for Novartis and has served on advisory boards for Yuhan. Z. Zhao is the speaker/advisor for and/or has received research funding from Novartis, Sanofi, Pfizer, Astellas, Galderma, Janssen, GlaxoSmithKline, Bayer, Leo, MEDA Pharma, and ALK Pharma. I. Nasr has been a speaker for Novartis, Sanofi, Takeda, and GlaxoSmithKline with no relation to the present manuscript. H. Rockmann‐Helmbach has received research funding from Pharming and Novartis Pharma, has received institution fees for advisory board activities from Sanofi, Third Harmonic Bio and Novartis, and has received speaker fees from Novartis Pharma. R. Ö. Kara has no conflicts of interest in relation to this manuscript. She has been a speaker for Novartis and Abbvie. R. Stepanenko has no conflicts of interest in relation to this manuscript. Outside it, he has conducted studies for/was an advisor for/was a speaker for Alvotech, GlaxoSmithKline, Mitsubishi Tanabe Pharma, Pfizer, Sanofi, and Uriach. M. Maurer or recently was a speaker and/or advisor for and/or has received research funding from Allakos, Alvotech, Amgen, Aquestive, Aralez, AstraZeneca, Bayer, Celldex, Celltrion, Evommune, GlaxoSmithKline, Ipsen, Kyowa Kirin, Leo Pharma, Lilly, Menarini, Mitsubishi Tanabe Pharma, Moxie, Noucor, Novartis, Orion Biotechnology, Resonance Medicine, Sanofi/Regeneron, Septerna, Third HarmonicBio, ValenzaBio, Yuhan Corporation, and Zurabio. S. Neisinger, B. Sousa Pinto, A. Ramanauskaite, C. A. S. Parisi, C. Guillet, L. Han, H Hardin, K. Godse, L. Lapiņa, S. Vandersee, A. Kurchenko, I. Kaidashev, V. Tsaryk, N. Kurjāne and J. Astrup Sørensen declare no conflicts of interest in relation to this work."

"Open Access funding enabled and organized by Projekt DEAL."